Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma

Beom Kyung Kim, Jun Yong Park, Hye Jin Choi, Do Young Kim, Sang Hoon Ahn, Ja Kyung Kim, Do Youn Lee, Kwang Hoon Lee, Kwang Hyub Han

Research output: Contribution to journalArticle

37 Citations (Scopus)


Purpose: Hepatic arterial infusion chemotherapy (HAIC) has often been used as a therapeutic option for patients with advanced hepatocellular carcinoma (HCC). This study aimed to evaluate the efficacy and safety of HAIC using cisplatin with or without 5-fluorouracil in patients with advanced HCC. Methods: Between January 2002 and December 2007, we enrolled patients with advanced HCC who underwent HAIC via implantable port systems with cisplatin (60 mg/m 2 on Day 1) with or without 5-fluorouracil (500 mg/m 2 on Days 1-3) every 4 weeks. Tumor response was assessed every two cycles. Results: During follow-up (median 9.5 months), we recorded patient (n = 138) and disease characteristics including median age (53 years), Child-Pugh class A/B (n = 103/35, respectively), portal vein thrombosis (n = 115), and death (n = 121). In total, 561 cycles of HAIC were administered (median four cycles, range 1-14). Ninety-one patients received cisplatin plus 5-fluorouracil, while 47 received only cisplatin. The median progression-free survival (PFS) and overall survival (OS) were 6.0 and 9.5 months, respectively, while the overall disease control rate was 62.3% (3 complete responses, 29 partial responses and 54 stable diseases). Patients treated with cisplatin plus 5-fluorouracil had longer median PFS (7.0 vs. 4.6 months in those given cisplatin only; p = 0.004) and OS (12.0 vs. 7.5 months in those given cisplatin only; p = 0.001). Adverse reactions were tolerable and successfully managed with conservative treatment. Conclusions: Repetitive HAIC seems well-tolerated and effective in treating advanced HCC, with more therapeutic benefit when treated with cisplatin plus 5-fluorouracil. Future randomized comparative studies are warranted for its efficacy.

Original languageEnglish
Pages (from-to)659-667
Number of pages9
JournalJournal of cancer research and clinical oncology
Issue number4
Publication statusPublished - 2011 Apr 1


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this